review article | Q7318358 |
scholarly article | Q13442814 |
P2093 | author name string | David Durantel | |
P433 | issue | 8 | |
P304 | page(s) | 860-870 | |
P577 | publication date | 2009-08-01 | |
P1433 | published in | Current Opinion in Investigational Drugs | Q15724634 |
P1476 | title | Celgosivir, an alpha-glucosidase I inhibitor for the potential treatment of HCV infection | |
P478 | volume | 10 |
Q35676012 | A Novel Iminosugar UV-12 with Activity against the Diverse Viruses Influenza and Dengue (Novel Iminosugar Antiviral for Influenza and Dengue) |
Q40368500 | Antiviral screening identifies adenosine analogs targeting the endogenous dsRNA Leishmania RNA virus 1 (LRV1) pathogenicity factor. |
Q38118461 | Antiviral therapies targeting host ER alpha-glucosidases: current status and future directions |
Q38159719 | Bitter-sweet symphony: glycan-lectin interactions in virus biology |
Q29994527 | Broad-spectrum agents for flaviviral infections: dengue, Zika and beyond |
Q33930289 | Comparative Analysis of Protein Glycosylation Pathways in Humans and the Fungal Pathogen Candida albicans |
Q26828727 | Curing a viral infection by targeting the host: the example of cyclophilin inhibitors |
Q28542607 | Dengue therapeutics, chemoprophylaxis, and allied tools: state of the art and future directions |
Q34306359 | Diastereoselective Nitrenium Ion-Mediated Cyclofunctionalization: Total Synthesis of (+)-Castanospermine |
Q47558474 | Enhancing the antiviral potency of ER α-glucosidase inhibitor IHVR-19029 against hemorrhagic fever viruses in vitro and in vivo |
Q26257542 | Extended Evaluation of Virological, Immunological and Pharmacokinetic Endpoints of CELADEN: A Randomized, Placebo-Controlled Trial of Celgosivir in Dengue Fever Patients |
Q53683152 | Glycan Shielding and Modulation of Hepatitis C Virus Neutralizing Antibodies. |
Q34235286 | Hepatitis C virus experimental model systems and antiviral drug research |
Q26779128 | Host-Targeting Agents to Prevent and Cure Hepatitis C Virus Infection |
Q55280981 | Host-targeting therapies for hepatitis C virus infection: current developments and future applications. |
Q34403294 | Identification of hepatitis C virus inhibitors targeting different aspects of infection using a cell-based assay |
Q37584342 | Imino sugar glucosidase inhibitors as broadly active anti-filovirus agents |
Q94561396 | Iminosugars With Endoplasmic Reticulum α-Glucosidase Inhibitor Activity Inhibit ZIKV Replication and Reverse Cytopathogenicity in vitro |
Q35191986 | In vivo therapeutic protection against influenza A (H1N1) oseltamivir-sensitive and resistant viruses by the iminosugar UV-4. |
Q41687420 | Inhibition of endoplasmic reticulum-resident glucosidases impairs severe acute respiratory syndrome coronavirus and human coronavirus NL63 spike protein-mediated entry by altering the glycan processing of angiotensin I-converting enzyme 2. |
Q39617748 | Inhibitors of endoplasmic reticulum alpha-glucosidases potently suppress hepatitis C virus virion assembly and release |
Q38597477 | Isothiazolo[4,3-b]pyridines as inhibitors of cyclin G associated kinase : synthesis, structure-activity relationship studies and antiviral activity. |
Q59360239 | Mechanisms of Antiviral Activity of Iminosugars Against Dengue Virus |
Q89725380 | Medicinal chemistry strategies toward host targeting antiviral agents |
Q34130399 | New antiviral therapies for chronic hepatitis C |
Q38238424 | New pharmacological strategies to fight enveloped viruses |
Q90669855 | Opportunities and Risks of Host-targeting Antiviral Strategies for Hepatitis C |
Q34576190 | Potential treatment options and future research to increase hepatitis C virus treatment response rate |
Q40251429 | Small molecule inhibitors of ER α-glucosidases are active against multiple hemorrhagic fever viruses |
Q42279828 | Steviamine, a new class of indolizidine alkaloid [(1R,2S,3R,5R,8aR)-3-hydroxy-meth-yl-5-methyl-octa-hydro-indolizine-1,2-diol hydro-bromide]. |
Q90737186 | Structure-Based Design of Antivirals against Envelope Glycoprotein of Dengue Virus |
Q38615654 | Targeting HCV entry for development of therapeutics |
Q37699395 | Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. |
Q35656099 | Viral resistance of MOGS-CDG patients implies a broad-spectrum strategy against acute virus infections |
Q37666750 | West Nile virus drug discovery |
Search more.